Coherus BioSciences Inc at Jefferies London Healthcare Conference Transcript
Good morning, everyone. Thanks for coming. Very close to the action here. (inaudible) analyst at Jefferies, and we're delighted to have with us Denny Lanfear, Founder (inaudible) the guy who brings in all the revenue. (inaudible) access. We're going to do a fireside chat, which is a great way to get us going forward.
So Denny and Jim, welcome. Thanks for coming to London.
Thank you for having us.
Questions & Answers
So let's start to talk. So after a period of debate, lots of work on the regulatory front, sorting out patent litigation, biosimilars have finally arrived in the U.S. It seems like we've been talking about them forever. Obviously, Coherus has executed really well on your initial opportunity, which competes in the $4 billion Neupogen market. Can you, Denny, give us an update on where Coherus is now? You launched UDENYCA in January, and it's done really well, posting Q3 sales well
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
